Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.

Cancer biology & therapy - 3 Jun 2017

Jin Juan, Zhang Wenwen, Ji Wenfei, Yang Fang, Guan Xiaoxiang

Abstract excerpt

Treatment of triple negative breast cancer (TNBC) has been a big challenge since it is defined. To date, platinum-based chemotherapy has played a significant role in the treatment of TNBC patients. However, some patients do not respond to platinum salts or gradually develop chemoresistance, resulting in little effect, or even some adverse effects. Here, we review numerous preclinical and clinical investigations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to DNA End-Joining Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Mutation

Share to Platinum Compounds

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28494179
DOI: 10.1080/15384047.2017.1323582
PMCID: PMC5536940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.PMID 28494179Read ↗

Platinum Salts in Patients with Breast Cancer: A Focus on Predictive FactorsSemantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read ↗

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair DeficiencySemantic proximity Read ↗

Triple-Negative Breast Cancer: Molecular Particularities Still a ChallengeSemantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Semantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.